Preclinical data demonstrated that KRAS-G12C inhibition drives antitumor immunity by enhancing the tumor microenvironment with CD8 T cells, macrophages, and CD103 cross-presenting dendritic cells (88). The gene discussed is CD8A; the disease is neoplasm.